Danaher (DHR) Scheduled to Post Earnings on Tuesday

Danaher (NYSE:DHR) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, April 23rd. Analysts expect the company to announce earnings of $1.74 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business had revenue of $6.41 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same period in the previous year, the firm earned $2.87 earnings per share. The firm’s quarterly revenue was down 10.2% compared to the same quarter last year. On average, analysts expect Danaher to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Danaher Stock Down 0.4 %

Shares of Danaher stock opened at $235.51 on Monday. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher has a 12 month low of $182.09 and a 12 month high of $259.00. The business has a fifty day simple moving average of $248.94 and a 200 day simple moving average of $230.25. The stock has a market cap of $174.40 billion, a PE ratio of 36.86, a price-to-earnings-growth ratio of 3.58 and a beta of 0.83.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be paid a dividend of $0.27 per share. The ex-dividend date is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. Danaher’s payout ratio is 16.90%.

Insiders Place Their Bets

In other news, Director Teri List sold 3,289 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Teri List sold 3,289 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock valued at $8,265,802 over the last 90 days. 11.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Danaher

Large investors have recently added to or reduced their stakes in the stock. Milestone Investment Advisors LLC acquired a new stake in Danaher during the first quarter worth approximately $153,000. Turim 21 Investimentos Ltda. grew its position in Danaher by 20.5% during the first quarter. Turim 21 Investimentos Ltda. now owns 511 shares of the conglomerate’s stock worth $150,000 after buying an additional 87 shares in the last quarter. Covestor Ltd grew its position in Danaher by 76.8% during the first quarter. Covestor Ltd now owns 495 shares of the conglomerate’s stock worth $145,000 after buying an additional 215 shares in the last quarter. Fortis Capital Advisors LLC bought a new stake in Danaher during the fourth quarter worth $108,000. Finally, Providence Capital Advisors LLC bought a new stake in Danaher during the first quarter worth $84,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research analyst reports. KeyCorp boosted their target price on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Barclays boosted their target price on Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 10th. Raymond James boosted their target price on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Citigroup boosted their target price on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $268.27.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.